Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Impact of Nutritional Supplementation on Sleep Quality
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 20, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of a Nutritional Supplement on Gut Microbiota in Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bonafide-HF3.0
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Lindus Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Hot Flash and Night Sweat Virtual Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 04, 2024
Lead Product(s) : Bonafide-HF3.0
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Lindus Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bonafide Pollen
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Bonafide Health
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Pharmavite will expand its portfolio of women's health by including Relizen (bonafide pollen), a plant-based & hormone-free supplement, which is safe to use for menopause relief.
Product Name : Relizen
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 30, 2023
Lead Product(s) : Bonafide Pollen
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Bonafide Health
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Triglyceride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of a Nutritional Supplement on Mental Wellness in Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Triglyceride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JDS-HF
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Herbal Nutraceutical Supplementation on Vasomotor Symptoms in Menopausal Women
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 14, 2023
Lead Product(s) : JDS-HF
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Nutrasource
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of Select Nutrients From Two Formulations of a Multivitamin/Mineral Supplement
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : S-Equol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable
A Nutritional Supplement on Vasomotor Symptoms in Women
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
August 18, 2020
Lead Product(s) : S-Equol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Biofortis Mérieux Nutriscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Melatonin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : KGK Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2019
Lead Product(s) : Melatonin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : KGK Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioavailability of EPA + DHA in a SMEDS Formulation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2018
Lead Product(s) : Icosapent Ethyl
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Midwest Center for Metabolic and Cardiovascular Research
Deal Size : Inapplicable
Deal Type : Inapplicable